news
AstraZeneca, Ionis' heart drug fails in major ATTR trial
AstraZeneca and Ionis' heart drug, eplontersen (Wainua), failed to meet its primary endpoint in a Phase 3 trial for ATTR-CM, a type of heart disease. The trial, dubbed CARDIO-TTRansform, did not show a statistically significant benefit in reducing cardiovascular death or hospitalizations compared to placebo. This marks a significant setback in a competitive market for treating this rare, progressive condition.
AstraZeneca and Ionis' heart drug, eplontersen (Wainua), failed to meet its primary endpoint in a Phase 3 trial for ATTR-CM, a type of heart disease. The trial, dubbed CARDIO-TTRansform, did not show a statistically significant benefit in reducing cardiovascular death or hospitalizations compared to placebo. This marks a significant setback in a competitive market for treating this rare, progressive condition.
The architecture take
Another drug, another fail. AstraZeneca and Ionis’s eplontersen, meant to tackle ATTR-CM heart disease, just flopped its main trial. While it’s already approved for a nerve condition, it seems like our hearts need a different hero. The drug was supposed to calm down the rogue proteins that gum up the heart. Instead, no dice on the big mortality and hospitalization numbers. This means the existing players, like Pfizer's Vyndaqel/Vyndamax and Alnylam's Amvuttra, can breathe a little easier for now. It’s a reminder that even huge pharma companies with deep pockets don't always crack the code on complex diseases, and sometimes, the human body is just too stubborn to cooperate. Keep watching this space; the unmet need for effective, safe heart disease treatments means someone else is already cooking up the next potential blockbuster.